YT 16-107 - research, DEV., and prod., of mrna vaccine antigens
Ended Awarded Last action
- Contract number
- HHSN26100029
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,050,014
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 100% obligated
- $3,050,014.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost No Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Economy Act FAR subpart 17.5
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $35,050 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $3,014,964 |
About this award
This is a delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The $3,050,014.00 contract is for research, development, and production of mRNA vaccine antigens. This contract does not have a set-aside designation. Leidos Biomedical Research Inc. provides a broad range of research, development, and production services to federal agencies, with a focus on supporting biomedical research programs at the NIH. The company holds an Indefinite Delivery Contract worth up to $6.6 billion from the National Cancer Institute to deliver a wide range of services through individual task orders. This task order supports the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program.
Quick answers
Who was awarded contract HHSN26100029?
HHSN26100029 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2016.
How much is contract HHSN26100029 worth?
The government has obligated $3,050,014 on HHSN26100029.
Which agency awarded contract HHSN26100029?
National Cancer Institute (National Institutes of Health) awarded HHSN26100029, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract HHSN26100029 an order under another contract?
Yes. HHSN26100029 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract HHSN26100029 competed?
The extent of competition for HHSN26100029 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award